SciSparc Announces 1-for-21 Reverse Share Split

Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases [6] - The company is engaged in drug development programs including SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus, utilizing cannabinoid pharmaceuticals [6] Reverse Share Split Announcement - The company announced a one-for-twenty one (1-for-21) reverse share split effective July 3, 2025, reducing the number of outstanding shares from approximately 11,225,751 to about 534,600 [1][4] - Following the reverse share split, approximately 516,727 shares will be publicly held, and the shares will continue to trade on the Nasdaq under the symbol "SPRC" [1] Shareholder Impact - The reverse share split will affect all shareholders uniformly, maintaining their percentage of ownership, with minor adjustments for fractional shares [4] - Fractional shares will not be issued; instead, they will be rounded to the nearest whole share [4] Share Capital and Options - The reverse share split will not adjust the authorized share capital, which remains at 75,000,000 Ordinary Shares [3] - There will be proportionate adjustments to the exercise price and the number of shares for all outstanding options and warrants [4] Shareholder Actions - Shareholders holding shares in book-entry form or through brokerage accounts do not need to take any action as the exchange will be processed automatically [5]